Big Money Sentiment increased to 1.47 in Q2 2018. It has change of 0.01, from 2018Q1’s 1.46. The ratio increased due to TG Therapeutics, Inc. positioning: 17 sold and 28 reduced. 22 funds acquired holdings and 44 increased holdings. Investors holded 37.47 million in 2018Q1 but now own 39.66 million shares or 5.82% more.
Swiss Fincl Bank reported 96,200 shs stake. The New York-based D E Shaw has invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Gam Ag reported 98,600 shs. Royal Commercial Bank Of Canada accumulated 0% or 14,198 shs. First Mercantile Tru reported 20,223 shs stake. Hikari has 160,000 shs for 0.23% of their capital. Victory Management holds 0% of its capital in TG Therapeutics, Inc. (NASDAQ:TGTX) for 1,841 shs. Citigroup stated it has 0% of its capital in TG Therapeutics, Inc. (NASDAQ:TGTX). Tiaa Cref Investment Mngmt Limited Liability holds 0% of its capital in TG Therapeutics, Inc. (NASDAQ:TGTX) for 124,424 shs. Tci Wealth Advsr reported 100 shs. Susquehanna Group Llp has 315,694 shs. California State Teachers Retirement Sys owns 90,540 shs or 0% of their US capital. Vantage Investment Advisors Ltd Limited Liability Company accumulated 150 shs or 0% of the stock. Morgan Stanley has 0% invested in TG Therapeutics, Inc. (NASDAQ:TGTX). Birchview Cap Ltd Partnership owns 15,000 shs or 0.13% of their US capital.
TG Therapeutics, Inc. registered $960,508 net activity with 0 insider purchases and 2 insider sales since June 14, 2018. $337,205 worth of TG Therapeutics, Inc. (NASDAQ:TGTX) was sold by KENNEDY WILLIAM JAMES on Thursday, June 14.
TG Therapeutics Inc (NASDAQ:TGTX) had an increase of its short interest by 0.73%. In November was issued TGTX’s total 9.95M short interest by FINRA. Previously was reported up change of 0.73% from 9.88M shares. 10 days will cost TGTX with 955,300 average volume to recover its former position. TG Therapeutics Inc float short is 18.54%.
Ticker’s shares touched $5.54 during the last trading session after 5.93% change.TG Therapeutics, Inc. has 1.81M shares volume, 10.38% up from normal. TGTX is downtrending and has moved 4.55% since November 10, 2017. The stock underperformed the S&P 500 by 20.17%.
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States.The firm is valued at $457.04 million. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin??s lymphoma and chronic lymphocytic leukemia.Last it reported negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.
TG Therapeutics, Inc. (NASDAQ:TGTX) Ratings Coverage
In total 2 analysts cover TG Therapeutics (NASDAQ:TGTX). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. (NASDAQ:TGTX) has 100% bullish analysts. 2 are the (NASDAQ:TGTX)’s ratings reports on Nov 10, 2018 according to StockzIntelligence Inc. On Monday, June 4 the rating was maintained by FBR Capital with “Buy”. On Tuesday, September 25 Raymond James downgraded TG Therapeutics, Inc. (NASDAQ:TGTX) rating. Raymond James has “Outperform” rating and $12 target.
A couple more TG Therapeutics, Inc. (NASDAQ:TGTX) news were released by: Nasdaq.com which released on November 07, 2018 “TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2018 Financial Results and Business Update”, also Seekingalpha.com on November 09, 2018 released “TG Therapeutics’ (TGTX) CEO Michael Weiss on Q3 2018 Results – Earnings Call Transcript”, the next Seekingalpha.com is “TG Therapeutics: What’s Ahead For This Oncology Concern” on October 31, 2018. Globenewswire.com has article titled “TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2018 Financial Results”.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.